High follicle-stimulating hormone (FSH) levels are almost always a signal from your body that something else is going on, and genuinely lowering them requires addressing that underlying cause rather than chasing the number itself. In women, the most common driver is a shrinking pool of eggs in the ovaries; in men, it usually reflects damaged or underperforming testicular tissue. The treatments that bring FSH down range from hormone replacement therapy and medications that act on the brain’s signaling pathway, to supplements, lifestyle changes, and still-experimental procedures like platelet-rich plasma injections. But the critical starting point is understanding why FSH climbed in the first place, because an effective strategy for a 28-year-old with premature ovarian insufficiency looks nothing like one for a 52-year-old in menopause or a man with a low sperm count.
Why FSH Goes Up in the First Place
FSH is produced by the pituitary gland in your brain, and its job is to stimulate the ovaries (in women) or the testes (in men) to do their work: maturing eggs or producing sperm. The system runs on a feedback loop. When the ovaries produce enough estradiol and a protein called inhibin, those signals travel back to the brain and tell the pituitary to ease off on FSH. Estradiol plays a particularly dominant role in dialing FSH back down during certain phases of the menstrual cycle, while inhibin becomes more important as follicles mature.1The Journal of Clinical Endocrinology & Metabolism. Control of Follicle-Stimulating Hormone by Estradiol and the Inhibins: Critical Role of Estradiol at the Hypothalamus during the Luteal-Follicular Transition When the ovaries or testes can no longer hold up their end of the conversation, the pituitary compensates by pumping out more FSH, like someone shouting louder into a phone when they can’t hear a response.
In women under 40, persistently elevated FSH alongside absent periods and low estrogen points to premature ovarian insufficiency, a condition in which the ovaries stop functioning years ahead of the typical menopausal timeline.2PubMed Central. Premature ovarian failure In men, elevated FSH is a marker for impaired sperm production and often indicates primary testicular failure, where the problem sits in the testes themselves rather than the brain’s signaling.3PubMed. Redefining abnormal follicle-stimulating hormone in the male infertility population The hormone profile in these cases typically shows high FSH and LH alongside low-to-normal testosterone and undetectable inhibin B.4The Journal of Clinical Endocrinology & Metabolism. Male infertility due to testicular disorders
This distinction matters because it determines what “reducing FSH” actually means for you. If the ovaries or testes are genuinely failing, you can suppress the pituitary’s FSH output with medication, but that doesn’t fix the underlying organ. On the other hand, if something reversible is pushing FSH up, like heavy smoking, chronic stress, or certain environmental exposures, removing that factor may let the feedback loop recover on its own.
The Measurement Problem
Before pursuing any treatment based on a single FSH reading, it is worth knowing that the number is less stable than most people assume, especially in premenopausal women. A study looking at the reliability of a single FSH measurement found that in premenopausal women, the reliability coefficient was only 0.09, compared to 0.70 in postmenopausal women. The difference came down to dramatically higher within-person variability before menopause, with the within-subject variance about 15 times greater in premenopausal women.5PubMed Central. Reliability of follicle-stimulating hormone measurements in serum In practical terms, a single elevated FSH result in a younger woman may not reflect her true baseline at all.
FSH values also fluctuate throughout the menstrual cycle, which is why clinicians typically draw blood on cycle day two or three when assessing ovarian reserve. Even then, FSH is considered a less reliable marker than anti-Müllerian hormone (AMH) or antral follicle count (AFC), both of which are more stable across the cycle and more predictive of ovarian reserve. FSH remains widely used in settings where AMH testing is expensive or unavailable, but a borderline-high FSH reading on a single draw deserves confirmation before anyone acts on it.6PubMed Central. Correlation of Follicle-stimulating Hormone, Anti-Mullerian Hormone, and Antral Follicle Count with Age in Ovarian Reserve Testing
Hormone Replacement Therapy
The most straightforward pharmacological way to lower FSH is to supply the hormones the body is no longer making on its own. In postmenopausal women, hormone replacement therapy (HRT) that delivers estradiol restores the feedback signal and brings FSH down. A systematic review and meta-analysis found that both oral and transdermal forms of HRT increase estradiol and reduce FSH compared with pre-treatment levels. Vaginal estrogen, however, did not produce the same systemic effect on FSH.7PubMed. Association between hormone replacement therapy and sex hormones in postmenopausal women: a systematic review and meta-analysis For women with premature ovarian insufficiency, HRT serves a dual purpose: it manages menopausal symptoms and protects bone density, while also normalizing the gonadotropin levels that have spiked in the absence of ovarian function.
HRT is effective at moving the FSH number, but it does not restore fertility. The ovaries are not being reactivated; rather, the pituitary simply receives the estradiol signal it was missing and stops overproducing FSH. For women hoping to conceive, HRT alone is not a path forward, though it is sometimes used as a priming strategy before fertility treatments.
GnRH Agonists and Antagonists
Another class of drugs targets the signaling system one step upstream of FSH. Gonadotropin-releasing hormone (GnRH) is the brain’s command signal that tells the pituitary to release FSH and LH. GnRH agonists and antagonists both shut down this command, but by different mechanisms. Agonists flood the pituitary’s receptors with a sustained signal, which initially causes a burst of FSH and LH release but within about two weeks leads to desensitization, so the pituitary essentially stops responding. Antagonists take a more direct route by blocking the receptors outright, producing an immediate drop in both hormones.8PubMed. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action
In fertility medicine, these drugs are used routinely during IVF cycles to prevent a premature LH surge that would trigger ovulation before eggs can be retrieved.9PubMed Central. Gonadotropin-releasing hormone analogs: Understanding advantages and limitations Outside of reproductive medicine, GnRH antagonists have shown an ability to suppress FSH more profoundly than agonists, a distinction that has drawn interest in prostate cancer treatment, where deeper FSH suppression appears linked to better tumor control.10PubMed. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist These are powerful medications with wide-reaching hormonal effects, so they are prescribed in controlled clinical settings rather than as standalone FSH-lowering agents.
DHEA and CoQ10 Supplementation
For women with diminished ovarian reserve who are trying to conceive, two supplements have accumulated enough clinical evidence to be part of the conversation, though neither is a guaranteed fix. Dehydroepiandrosterone (DHEA) is a hormone precursor that the body can convert into estrogen and testosterone. A review of the evidence concluded that DHEA supplementation improves ovarian function, increases pregnancy chances, and may lower miscarriage rates by reducing chromosomal abnormalities in eggs. Over time, DHEA appeared to improve measurable markers of ovarian reserve.11PubMed Central. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR) Because better ovarian function means more inhibin and estradiol feeding back to the pituitary, FSH can drop as a downstream consequence.
Coenzyme Q10 (CoQ10) works through a different pathway. It supports mitochondrial energy production in eggs, which matters because egg cells are among the most energy-hungry cells in the body. A randomized controlled trial in young women with diminished ovarian reserve found that CoQ10 pretreatment led to more eggs retrieved during IVF, a higher fertilization rate, and more high-quality embryos.12PubMed Central. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial Broader reviews support the idea that CoQ10 improves oocyte quality and ovarian function, particularly in older women or those with weak ovarian reserve.13PubMed Central. Exploring the protective effects of coenzyme Q10 on female fertility Neither DHEA nor CoQ10 is likely to normalize FSH in someone whose ovaries have truly stopped working, but for women in a gray zone of declining reserve, these supplements can meaningfully improve the picture.
Lifestyle Factors That Move the Needle
Smoking is one of the clearest modifiable risk factors for elevated FSH. A study of premenopausal women found that current smokers had FSH concentrations about 66% higher than nonsmokers who were not exposed to passive smoke. Even passive smoke exposure was associated with roughly 39% higher FSH levels.14PubMed. Follicle-stimulating hormone concentrations in relation to active and passive smoking Separate research has confirmed that moderate smoking raises daily urinary FSH by at least 30 to 35%, consistent with tobacco chemicals damaging ovarian tissue and disrupting the hormone feedback loop.15PubMed Central. Cigarette smoking and effects on hormone function in premenopausal women Quitting smoking will not reverse ovarian aging that has already occurred, but removing the ongoing toxic insult gives remaining ovarian tissue the best chance of functioning normally.
Body weight also plays a role, though the relationship is more nuanced than “lose weight to fix FSH.” In postmenopausal women, obesity is actually associated with lower FSH levels compared to normal-weight peers, likely because fat tissue produces estrone (a form of estrogen) that partially maintains the feedback signal.16PubMed Central. Obesity and Reproductive Hormone Levels in the Transition to Menopause Before menopause, though, obesity can disrupt ovulation and hormonal cycling in other ways. The upshot is that there is no simple body-weight prescription for lowering FSH; the interaction depends on your reproductive stage and individual hormonal profile.
Psychological stress represents another route. A prospective study found that perceived stress activates the body’s stress-response system, which in turn can inhibit the LH surge needed for ovulation. Higher FSH levels were observed in women under greater stress, consistent with the ovaries being less responsive and the pituitary ramping up its signal to compensate.17PubMed Central. Perceived stress, reproductive hormones, and ovulatory function: a prospective cohort study Stress reduction alone is unlikely to normalize severely elevated FSH, but chronic stress layered on top of borderline ovarian function can make things measurably worse.
Environmental Exposures Worth Knowing About
Certain chemicals in everyday products may accelerate the ovarian decline that drives FSH upward. Phthalates (found in plastics, personal care products, and food packaging) and bisphenol A (BPA) have both been studied for their effects on reproductive organs. Women diagnosed with primary ovarian insufficiency were found to have significantly higher blood levels of phthalate metabolites, particularly mono-butyl phthalate, compared to women with normal ovarian function.18PubMed. Serum levels of phthalates and bisphenol-A in patients with primary ovarian insufficiency This does not prove that phthalates caused the condition, but the association is strong enough that reducing exposure to plasticizers and endocrine disruptors is a reasonable precautionary step, especially for women already concerned about ovarian reserve.
Practical steps include avoiding heating food in plastic containers, choosing fragrance-free personal care products, and filtering drinking water. These changes will not reverse established ovarian insufficiency, but they remove a potential contributor to ongoing ovarian stress. Dietary pattern may matter too: one study found that obese women who ate a “prudent” dietary pattern rich in vegetables, fruit, fish, and whole grains had higher antral follicle counts and AMH levels than those eating a Western-style diet heavy in processed food and red meat.19PubMed Central. Associations between dietary patterns and parameters of ovarian reserve in Polish women of reproductive age The study did not directly measure FSH changes, but since AFC and AMH reflect the same ovarian reserve that governs FSH feedback, the link is biologically plausible.
The Male Side of the Equation
High FSH in men requires a different treatment logic. In men whose FSH is high because the testes are underperforming (primary testicular failure), the goal is not to suppress FSH but to support whatever testicular function remains. Paradoxically, some men with infertility are actually given FSH as a treatment rather than having it reduced. FSH therapy is most clearly effective in men with hypogonadotropic hypogonadism, where the problem is that the brain is not producing enough FSH in the first place. In those men, supplemental FSH stimulates sperm production with good results.20PubMed. Follicle-stimulating hormone treatment for male factor infertility
For men whose FSH is already elevated, treatment typically focuses on optimizing testosterone production from the Leydig cells in the testes, stimulating Sertoli cells (which nurture developing sperm), and correcting the testosterone-to-estrogen ratio.21PubMed Central. Medical treatment of male infertility Clomiphene citrate and aromatase inhibitors are sometimes used off-label for this purpose. The key point is that in men, the clinical focus is almost never on bringing FSH down; it is on improving sperm output and hormonal balance, with FSH as a diagnostic marker rather than a treatment target.
Platelet-Rich Plasma Injections
One of the more intriguing experimental approaches for women is intraovarian injection of platelet-rich plasma (PRP), a concentrate made from the patient’s own blood. The idea is that growth factors in PRP may reactivate dormant follicles or improve the ovarian environment. A systematic review and meta-analysis found that FSH dropped significantly in every month measured after PRP treatment, with the largest drop (roughly 10 mIU/mL) at the one-month mark and sustained reductions of about 7 to 9 mIU/mL through three months.22PubMed Central. Platelet-rich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis
A large single-center study of 469 women found statistically significant normalization of FSH values by the third and fourth months after PRP injection across all age groups.23PubMed Central. Intraovarian Platelet-Rich Plasma Injections: Safety and Thoughts on Efficacy Based on a Single Centre Experience With 469 Women Another study of 510 women with poor ovarian response reported that PRP improved ovarian reserve markers, yielded a pregnancy rate of about 20%, and a live birth rate of roughly 13%.24PubMed Central. Ovarian reserve parameters and IVF outcomes in 510 women with poor ovarian response (POR) treated with intraovarian injection of autologous platelet rich plasma (PRP) These numbers are encouraging for a population that usually has very limited options, but PRP is still considered experimental. There are no large, blinded, placebo-controlled trials yet, and the mechanism by which PRP might restart follicle activity remains unclear.
Stem Cell Therapy on the Horizon
Even more experimental is stem cell therapy for premature ovarian insufficiency. A meta-analysis pooling animal and human studies found that stem cell transplantation lowered FSH levels in both settings. In the clinical studies specifically, stem cell therapy decreased FSH, increased antral follicle count, and was associated with higher pregnancy and live birth rates in women with premature ovarian insufficiency.25PubMed. Stem cell therapy for premature ovarian insufficiency: a systematic review and meta-analysis of animal and clinical studies The clinical data came from small, early-phase trials, so these results are preliminary. Stem cell therapy for ovarian failure is not available as a standard treatment anywhere and will need substantially more evidence before it could be recommended outside of a research protocol.
When High FSH Matters Beyond Fertility
Researchers have increasingly found that FSH does not just reflect the health of your gonads; it appears to directly affect other tissues. Epidemiological evidence links higher FSH levels with postmenopausal osteoporosis and cardiovascular disease.26Trends in Endocrinology & Metabolism. Non-Gonadal Endocrine Actions of Follicle-Stimulating Hormone A study of older adults found that higher FSH was associated with roughly a 20% increased risk of hip fracture, even after accounting for estradiol and testosterone levels.27PubMed Central. Higher FSH Level Is Associated With Increased Risk of Incident Hip Fracture in Older Adults, Independent of Sex Hormones That “independent of sex hormones” part is the striking finding: it suggests FSH itself may directly weaken bone, not just serve as a passive marker of estrogen decline.
This has sparked interest in the possibility that blocking FSH’s action could one day treat osteoporosis, obesity, and even cognitive decline in aging populations. Early research suggests that FSH may influence fat accumulation and has been tentatively linked to Alzheimer’s risk.28PubMed Central. Targeting FSH for osteoporosis, obesity, and Alzheimer’s disease These connections are still being worked out, but they add another dimension to why high FSH is worth paying attention to even if you are not trying to get pregnant. The therapeutic opportunity here is genuinely new territory: drugs that specifically neutralize FSH (rather than broadly suppressing all pituitary hormones) are in early development and could eventually offer a way to address the skeletal and metabolic consequences of rising FSH during aging.
IVF Strategies for Women With High FSH
For women actively trying to conceive through IVF, a high FSH reading can feel like a door slamming shut. Clinics sometimes use FSH thresholds to screen patients, and an elevated level may lead to a recommendation to use donor eggs. But the picture is more textured than a single cutoff. Some clinics use mild stimulation protocols, which involve lower doses of medications or oral drugs like letrozole, on the logic that bombarding aging ovaries with high-dose hormones does not necessarily yield better results. A systematic review comparing mild and conventional stimulation found no meaningful difference in live birth rates for poor responders.29PubMed Central. Mild versus conventional ovarian stimulation for IVF in poor, normal and hyper-responders: a systematic review and meta-analysis This challenges the assumption that more aggressive stimulation is always better when ovarian reserve is low, and it means that a gentler, less expensive approach can be a reasonable option.
The broader point for anyone navigating this is that a high FSH number does not erase your options. It narrows them, and it shifts the odds, but the combination of accurate diagnostic workup, appropriate supplementation, and an IVF protocol matched to your situation can still produce results. What matters more than chasing a lower FSH number is finding a clinician who treats the whole clinical picture rather than acting on a single hormone value in isolation.